Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar SorrySam (73.24) Submitted: 3/19/2011 12:23:54 AM : Outperform Start Price: $1.55 DYAX Score: +8.20

insider buying

Featured Broker Partners


Advertisement